Regimen for enzymatic desensitisation
AssigneeHansa Biopharma AB
InventorsSofia Järnum, Christian Kjellman
Life of this patent
Estimating the term…
Abstract
The present invention relates to a conditioning regimen for a cell transplant to a sensitized subject, which is optionally of hematopoietic stem/progenitor cells (HSPC). The invention also relates to methods comprising administration of a cell transplant to a sensitized subject in accordance with the conditioning regimen, for the prevention or treatment of immune rejection of a cell transplant, for the prevention or treatment of engraftment failure or poor graft function of a cell transplant, or for the prevention or treatment of a disease or condition that is treated or prevented by a cell transplant. The invention also provides methods for determining whether a patient is sensitized and hence that the conditioning regimen should be used.
Claims15
A conditioning regimen for a cell transplant to a sensitized subject, comprising:
- a. administering to the subject a dose of an enzyme which inactivates serum IgG molecules in the subject;
- b. subsequently administering the transplant to the subject;
- c. subsequently administering to the subject a further dose of an enzyme which inactivates serum IgG molecules in the subject, which is optionally the same enzyme as in step a.
Dependencies are inferred from the claim text.